# Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

> **NCT02589340** · PHASE1 · TERMINATED · sponsor: **Oregon Health and Science University** · enrollment: 6 (actual)

## Conditions studied

- Parkinson's Disease
- Dyskinesias
- Movement Disorders

## Interventions

- **DRUG:** Buspirone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02589340
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2021-02-23
- **Final completion:** 2021-02-23
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2021-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02589340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02589340, "Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02589340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*